ArticleFrontiers in psychiatry2023
Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa.
Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The Efficacy of Pharmacological Treatment of Depression in Anorexia Nervosa and Underweight Patients: A Systematic Review.European eating disorders review : the journal of the Eating Disorders Association · 2026Pooled it
- Ketamine for mood disorders, anxiety, and suicidality in children and adolescents: a systematic review.European child & adolescent psychiatry · 2025Pooled it
- Understanding experiences of psychedelic treatments for eating disorders: a meta-synthesis of qualitative studies.BMC medicine · 2026Review
- Olanzapine for young people with anorexia nervosa: a synopsis of the main results from the OPEN open-label feasibility study.Health technology assessment (Winchester, England) · 2026Article
- Pathways to improved treatment of anorexia nervosa: a need for reconceptualization.Journal of eating disorders · 2026Article
- Eating and Mental Health Disorders.Nutrients · 2026Article
- Ketamine for treatment resistant depression in individuals with eating disorders: a comparison study.Journal of eating disorders · 2025Article
- Novel potential pharmacological approaches in treating eating disorders comorbid with substance use disorders.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa.Journal of eating disorders · 2025Article
- Eating- and Weight-Related Disorders in the Armed Forces.Metabolites · 2024Review
- Pharmacotherapeutic strategies for the treatment of anorexia nervosa - novel targets to break a vicious cycle.Expert opinion on pharmacotherapy · 2024Review
- Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study.BMC psychiatry · 2024Article
- Improvement in depressive symptoms in a patient with severe and enduring anorexia nervosa and comorbid major depressive disorder using psychotherapy-assisted IV ketamine : a case report.Journal of eating disorders · 2024Article
- Established and emerging treatments for eating disorders.Trends in molecular medicine · 2024Review
- Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review.Frontiers in psychiatry · 2024Review
- What kind of illness is anorexia nervosa? Revisited: some preliminary thoughts to finding a cure.Journal of eating disorders · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A comorbid diagnosis of a depressive disorder is a negative prognostic factor for individuals with AN, and novel treatments are needed to target depressive symptoms in this population. One emerging promising treatment for depressive disorders is ketamine, although there is less research investigating the use of ketamine for alleviating depression in people with AN. Case report: This study reports on four patients with a lifetime diagnosis of AN and a comorbid diagnosis of major depressive disorder who received either intramuscular ketamine ( Discussion: These findings suggest that (es)ketamine may reduce depressive symptoms in people with major depressive disorder and a comorbid diagnosis of AN. Future feasibility and pilot trials are warranted in order to elicit robust data on efficacy, acceptability, safety and tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.